原发性肝癌基层筛查与健康监测管理的研究进展

doi:10.12114/j.issn.1007-9572.2023.0240

摘要/Abstract

摘要： 当前我国原发性肝癌（以下简称肝癌）的发病率和死亡率较高，经济和疾病负担沉重，对肝癌风险人群进行规范的筛查与健康监测管理是有效降低肝癌相关负担的重要措施。目前我国基层慢性肝病患者缺乏肝癌筛查与监测必要性的认知，依从性较差，现有的筛查工具灵敏度欠佳、成本效益较低。本文从我国慢性肝病人群肝癌发生风险的评估分层、基层筛查和肝癌高危人群的加强筛查与长期监测现状等方面探讨中国人群肝癌基层筛查与健康管理策略，为我国人群肝癌筛查与早诊、早治工作的规范开展提供参考，以期提升我国基层人群肝癌筛查覆盖率及防控效果。

关键词: 癌，肝细胞, 肝炎, 人口健康管理, 筛查, 人群监测, 社区卫生服务, 新进展

Abstract:

At present, the incidence and mortality of primary liver cancer (hereafter referred to as liver cancer) in China are high with heavy economic and disease burden. Standardized screening and health surveillance management for population as risk of liver cancer are important measures to effectively reduce the related burden of liver cancer. Currently, patients with liver cancer in primary care institutions in China lack the awareness of the necessity of liver cancer screening and surveillance with poor compliance, and the existing screening tools are less sensitive and cost-effective. This paper discusses the strategies of liver cancer screening and health surveillance management in primary care institutuons in terms of stratification of liver cancer risk assessment and screening in primary care institutions of chronic liver disease population in China, the current status of enhanced screening and long-term surveillance for population at high risk of liver cancer, to provide a reference for the standardization of screening, early diagnosis and treatment of liver cancer in China, with the aim of improving the screening coverage and control effects of liver cancer in primary care in China.

Key words: Carcinoma, hepatocellular, Hepatitis, Population health management, Screening, Population surveillance, Community health services, Review

路丽霞,王荣琦. 原发性肝癌基层筛查与健康监测管理的研究进展[J]. 中国全科医学, 2023, 26(36): 4505-4509. DOI: 10.12114/j.issn.1007-9572.2023.0240.
LU Lixia,WANG Rongqi. Advances in Liver Cancer Screening and Health Surveillance Management in Primary Care Institutions[J]. Chinese General Practice, 2023, 26(36): 4505-4509. DOI: 10.12114/j.issn.1007-9572.2023.0240.

参考文献 38

[1]	SUNG H, FERLAY J, SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021,71(3):209-249. DOI：10.3322/caac.21660.
[2]	冉建朝，王乐，张玥，等. 中国人群肝癌所致DALYs疾病负担：1990—2016年长期分析及预测[J]. 中国循证医学杂志，2018,18(5):401-409.
[3]	PAN R, ZHU M, YU C Q，et al. Cancer incidence and mortality：a cohort study in China，2008-2013[J]. Int J Cancer，2017,141(7):1315-1323. DOI：10.1002/ijc.30825.
[4]	赫捷，陈万青，沈洪兵，等. 中国人群肝癌筛查指南（2022，北京）[J]. 临床肝胆病杂志，2022,38(8):1739-1758,1954. DOI：10.3969/j.issn.1001-5256.2022.08.007.
[5]	SHARMA S A, KOWGIER M, HANSEN B E，et al. Toronto HCC risk index：a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis[J]. J Hepatol，2017:S0168-S8278(17)32248-1. DOI：10.1016/j.jhep.2017.07.033.
[6]	YANG H I, YUEN M F, CHAN H L，et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B （REACH-B）：development and validation of a predictive score[J]. Lancet Oncol，2011,12(6):568-574. DOI：10.1016/S1470-2045(11)70077-8.
[7]	FAN C S, LI M G, GAN Y，et al. A simple AGED score for risk classification of primary liver cancer：development and validation with long-term prospective HBsAg-positive cohorts in Qidong，China[J]. Gut，2019,68(5):948-949. DOI：10.1136/gutjnl-2018-316525.
[8]	PAPATHEODORIDIS G, DALEKOS G, SYPSA V，et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol，2016,64(4):800-806. DOI：10.1016/j.jhep.2015.11.035.
[9]	PAPATHEODORIDIS G V, SYPSA V, DALEKOS G N，et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B[J]. J Hepatol，2020,72(6):1088-1096. DOI：10.1016/j.jhep.2020.01.007.
[10]	FAN R, PAPATHEODORIDIS G, SUN J，et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol，2020,73(6):1368-1378. DOI：10.1016/j.jhep.2020.07.025.
[11]	李秀华，郝新，邓永红，等. 应用aMAP评分评估基层医院慢性肝病人群的肝癌发生风险[J]. 中华肝脏病杂志，2021,29(4):332-337. DOI：10.3760/cma.j.cn501113-20210329-00144.
[12]	HEIMBACH J K, KULIK L M, FINN R S，et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology，2018,67(1):358-380. DOI：10.1002/hep.29086.
[13]	TSILIMIGRAS D I, BAGANTE F, SAHARA K，et al. Prognosis after resection of Barcelona clinic liver cancer （BCLC）stage 0，A，and B hepatocellular carcinoma：a comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol，2019,26(11):3693-3700. DOI：10.1245/s10434-019-07580-9.
[14]	ALLEMANI C, MATSUDA T, CARLO V D，et al. Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet，2018,391(10125):1023-1075. DOI：10.1016/S0140-6736(17)33326-3.
[15]	卫生部办公厅关于印发2010年艾滋病等重大疾病防治项目管理方案的通知[EB/OL]. (2010-09-17)[2022-12-20].
[16]	卫生部办公厅关于印发《城市癌症早诊早治项目管理办法（试行）》的通知[EB/OL]. (2012-11-01)[2022-12-20].
[17]	中华预防医学会肝胆胰疾病预防与控制专业委员会，中国研究型医院学会肝病专业委员会，中华医学会肝病学分会，等. 原发性肝癌的分层筛查与监测指南（2020版）[J]. 中华肝脏病杂志，2021,29(1):25-40. DOI：10.3760/cma.j.cn112152-20201109-00970.
[18]	南月敏，高沿航，王荣琦，等. 原发性肝癌二级预防共识（2021年版）[J]. 临床肝胆病杂志，2021,37(3):532-542.
[19]	TZARTZEVA K, OBI J, RICH N E，et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis：a meta-analysis[J]. Gastroenterology，2018,154(6):1706-1718.e1. DOI：10.1053/j.gastro.2018.01.064.
[20]	LEE S, KIM S S, ROH Y H，et al. Diagnostic performance of CT/MRI liver imaging reporting and data system v2017 for hepatocellular carcinoma：a systematic review and meta-analysis[J]. Liver Int，2020,40(6):1488-1497. DOI：10.1111/liv.14424.
[21]	GOOSSENS N, SINGAL A G, KING L Y，et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis[J]. Clin Transl Gastroenterol，2017,8(6):e101. DOI：10.1038/ctg.2017.26.
[22]	KHATRI G, PEDROSA I, ANANTHAKRISHNAN L，et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis：an equivalence study using LI-RADS v2018[J]. J Magn Reson Imaging，2020,51(2):415-425. DOI：10.1002/jmri.26835.
[23]	YOON J H, LEE J M, LEE D H，et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development[J]. Liver Cancer，2020,9(5):503-517. DOI：10.1159/000506834.
[24]	JOHNSON P J, PIRRIE S J, COX T F，et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev，2014,23(1):144-153. DOI：10.1158/1055-9965.EPI-13-0870.
[25]	LIU M C, OXNARD G R, KLEIN E A，et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA[J]. Ann Oncol，2020,31(6):745-759. DOI：10.1016/j.annonc.2020.02.011.
[26]	林慧娴，郑磊. 液体活检在肿瘤领域的研究进展[J]. 实用医学杂志，2019,35(10):1685-1688. DOI：10.3969/j.issn.1006-5725.2019.10.035.
[27]	陈万青，李霓，曹毛毛，等. 2013—2017年中国城市癌症早诊早治项目基线结果分析[J]. 中国肿瘤，2020,29(1):1-6. DOI：10.11735/j.issn.1004-0242.2020.01.A001.
[28]	俞霞，程伟民，吴标华，等. 中山市小榄镇肝癌高危人群筛查依从性及筛查效果分析[J]. 中国肿瘤临床，2020,47(7):350-353. DOI：10.3969/j.issn.1000-8179.2020.07.111.
[29]	TRAN S A, LE A, ZHAO C Q，et al. Rate of hepatocellular carcinoma surveillance remains low for a large，real-life cohort of patients with hepatitis C cirrhosis[J]. BMJ Open Gastroenterol，2018,5(1):e000192. DOI：10.1136/bmjgast-2017-000192.
[30]	ZHAO C Q, JIN M J, LE R H，et al. Poor adherence to hepatocellular carcinoma surveillance：a systematic review and meta-analysis of a complex issue[J]. Liver Int，2018,38(3):503-514. DOI：10.1111/liv.13555.
[31]	CHEN Y W, LIU C C, PERNG D S. Perceptions about preventing hepatocellular carcinoma among patients with chronic hepatitis in hepatitis Taiwan [J]. World J Gastroenterol，2013,19(22):3459-3465. DOI：10.3748/wjg.v19.i22.3459.
[32]	DALTON-FITZGERALD E, TIRO J, KANDUNOORI P，et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis[J]. Clin Gastroenterol Hepatol，2015,13(4):791-798.e1. DOI：10.1016/j.cgh.2014.06.031.
[33]	YANG J D, MANNALITHARA A, PISCITELLO A J，et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis[J]. Hepatology，2018,68(1):78-88. DOI：10.1002/hep.29594.
[34]	白方舟，王乐，王宇婷，等. 中国肝癌筛查卫生经济学研究的系统评价[J]. 中国循证医学杂志，2018,18(5):442-449.
[35]	曹梦迪，王红，石菊芳，等. 中国人群肝癌疾病负担：多数据源证据更新整合分析[J]. 中华流行病学杂志，2020,41(11):1848-1858. DOI：10.3760/cma.j.cn112338-20200306-00271.
[36]	SINGAL A G, PILLAI A, TIRO J. Early detection，curative treatment，and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis：a meta-analysis[J]. PLoS Med，2014,11(4):e1001624. DOI：10.1371/journal.pmed.1001624.
[37]	国家卫生健康委员会疾病预防控制局，中国癌症基金会，农村癌症早诊早治项目专家委员会. 癌症早诊早治项目（农村）工作报告2019/2020[R]. 北京：国家卫生健康委员会疾病预防控制局，中国癌症基金会，2020.
[38]	KWON J W, TCHOE H J, LEE J，et al. The impact of national surveillance for liver cancer：results from real-world setting in Korea[J]. Gut Liver，2020,14(1):108-116. DOI：10.5009/gnl18522.